724 related articles for article (PubMed ID: 10027587)
1. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
[TBL] [Abstract][Full Text] [Related]
2. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model.
Koopmans SJ; Mroz Z; Dekker R; Corbijn H; Ackermans M; Sauerwein H
Metabolism; 2006 Jul; 55(7):960-71. PubMed ID: 16784971
[TBL] [Abstract][Full Text] [Related]
3. Masoprocol decreases serum triglyceride concentrations in rats with fructose-induced hypertriglyceridemia.
Scribner KA; Gadbois TM; Gowri M; Azhar S; Reaven GM
Metabolism; 2000 Sep; 49(9):1106-10. PubMed ID: 11016888
[TBL] [Abstract][Full Text] [Related]
4. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat.
Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Gadbois TM; Reaven GM
Metabolism; 2000 Nov; 49(11):1390-4. PubMed ID: 11092499
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM
Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Wang Y; Campbell T; Perry B; Beaurepaire C; Qin L
Metabolism; 2011 Feb; 60(2):298-305. PubMed ID: 20304443
[TBL] [Abstract][Full Text] [Related]
8. The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.
Gao L; Niu Y; Liu W; Xie M; Liu X; Chen Z; Li L
Clin Chim Acta; 2008 Feb; 388(1-2):89-94. PubMed ID: 17991430
[TBL] [Abstract][Full Text] [Related]
9. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic property of ethanolic extract of Andrographis paniculata in streptozotocin-diabetic rats.
Zhang XF; Tan BK
Acta Pharmacol Sin; 2000 Dec; 21(12):1157-64. PubMed ID: 11603293
[TBL] [Abstract][Full Text] [Related]
11. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
12. Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat.
Sahin K; Onderci M; Tuzcu M; Ustundag B; Cikim G; Ozercan IH; Sriramoju V; Juturu V; Komorowski JR
Metabolism; 2007 Sep; 56(9):1233-40. PubMed ID: 17697867
[TBL] [Abstract][Full Text] [Related]
13. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin.
Riccio A; Del Prato S; Vigili de Kreutzenberg S; Tiengo A
Diabete Metab; 1991 May; 17(1 Pt 2):180-4. PubMed ID: 1936473
[TBL] [Abstract][Full Text] [Related]
14. [Change of glucose transporter 4 and its influence on glucose and fatty-acid metabolism in type 2 diabetic myocardium].
Wen ZY; Wu Y; Li Y; Chen XL; Wang T; Ouyang JP; Li GS
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1460-3. PubMed ID: 16061022
[TBL] [Abstract][Full Text] [Related]
15. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
Nagi DK; Ali VM; Yudkin JS
Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Gad MZ; Ehssan NA; Ghiet MH; Wahman LF
Pak J Pharm Sci; 2010 Jul; 23(3):305-12. PubMed ID: 20566445
[TBL] [Abstract][Full Text] [Related]
17. Effects of new hypoglycemic agent A-4166 on lipolysis and lipogenesis in rat adipocytes.
Macho L; Fickova M; Zorad S; Sebokova E; Klimes I
Endocr Regul; 2000 Sep; 34(3):119-26. PubMed ID: 11074662
[TBL] [Abstract][Full Text] [Related]
18. The biomimetic [Cr(3)O(O(2)CCH(2)CH(3))(6)(H(2)O)(3)](+ )decreases plasma insulin, cholesterol, and triglycerides in healthy and type II diabetic rats but not type I diabetic rats.
Sun Y; Clodfelder BJ; Shute AA; Irvin T; Vincent JB
J Biol Inorg Chem; 2002 Sep; 7(7-8):852-62. PubMed ID: 12203022
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Arulmozhi DK; Kurian R; Bodhankar SL; Veeranjaneyulu A
J Pharm Pharmacol; 2008 Sep; 60(9):1167-73. PubMed ID: 18718120
[TBL] [Abstract][Full Text] [Related]
20. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
